Cristina Sempio1, Marilyn A Huestis2, Susan K Mikulich-Gilbertson3,4, Jost Klawitter1, Uwe Christians1, Thomas K Henthorn1,5. 1. Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA. 2. The Lambert Center for the Study of Medicinal Cannabis and Hemp, The Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. 3. Department of Psychiatry, Division of Substance Dependence, University of Colorado School of Medicine, Aurora, Colorado, USA. 4. Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora, Colorado, USA. 5. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.
Abstract
AIMS: Population pharmacokinetic models of Δ9-tetrahydrocannabinol (THC) have been developed for THC plasma and blood concentration data. Often, only the metabolites of THC are measurable when blood samples are obtained. Therefore, we performed a population pharmacokinetic analysis of THC, 11-OH-THC and THCCOOH plasma concentration data from a Phase I clinical trial of THC smoking. METHODS: Frequently obtained plasma THC, 11-OH-THC and THCCOOH concentration data were obtained over 168 h from 6 subjects who smoked low (15.8 mg) and high dose (33.8 mg) THC cigarettes on 2 occasions. Bayesian estimates of the THC pharmacokinetic model from each individual for each dose were fixed prior to the sequential pharmacokinetic analysis of the metabolites. RESULTS: A 3-compartment model of THC was developed that has a steady-state volume of distribution (VdSS ) of 3401 ± 788 L and a clearance of 0.72 ± 0.10 L/min. 11-OH-THC was characterized by 50 ± 6% of the THC being directly cleared to a 3-compartment model with a VdSS of 415.2 ± 4.3 L and clearance of 0.78 ± 0.05 L/min. The THCCOOH model shared the central compartment of the 11-OH-THC model with a VdSS of 29.1 ± 0.05 L and a clearance of 0.12 ± 0.02 L/min. First order kinetics were observed for THC and THCCOOH between the low and high doses, but a nonlinear pattern was observed for 11-OH-THC. CONCLUSION: We describe the pharmacokinetics of THC, 11-OH-THC and THCCOOH including inter- and intraindividual variability of the parameter estimates of the model.
AIMS: Population pharmacokinetic models of Δ9-tetrahydrocannabinol (THC) have been developed for THC plasma and blood concentration data. Often, only the metabolites of THC are measurable when blood samples are obtained. Therefore, we performed a population pharmacokinetic analysis of THC, 11-OH-THC and THCCOOH plasma concentration data from a Phase I clinical trial of THC smoking. METHODS: Frequently obtained plasma THC, 11-OH-THC and THCCOOH concentration data were obtained over 168 h from 6 subjects who smoked low (15.8 mg) and high dose (33.8 mg) THC cigarettes on 2 occasions. Bayesian estimates of the THC pharmacokinetic model from each individual for each dose were fixed prior to the sequential pharmacokinetic analysis of the metabolites. RESULTS: A 3-compartment model of THC was developed that has a steady-state volume of distribution (VdSS ) of 3401 ± 788 L and a clearance of 0.72 ± 0.10 L/min. 11-OH-THC was characterized by 50 ± 6% of the THC being directly cleared to a 3-compartment model with a VdSS of 415.2 ± 4.3 L and clearance of 0.78 ± 0.05 L/min. The THCCOOH model shared the central compartment of the 11-OH-THC model with a VdSS of 29.1 ± 0.05 L and a clearance of 0.12 ± 0.02 L/min. First order kinetics were observed for THC and THCCOOH between the low and high doses, but a nonlinear pattern was observed for 11-OH-THC. CONCLUSION: We describe the pharmacokinetics of THC, 11-OH-THC and THCCOOH including inter- and intraindividual variability of the parameter estimates of the model.
Authors: Erin L Karschner; W David Darwin; Robert S Goodwin; Stephen Wright; Marilyn A Huestis Journal: Clin Chem Date: 2010-11-15 Impact factor: 8.327
Authors: Nathalie A Desrosiers; Sarah K Himes; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis Journal: Clin Chem Date: 2014-02-21 Impact factor: 8.327
Authors: Kelly Jonkman; Andreas Duma; Erik Olofsen; Thomas Henthorn; Monique van Velzen; René Mooren; Liesbeth Siebers; Jojanneke van den Beukel; Leon Aarts; Marieke Niesters; Albert Dahan Journal: Anesthesiology Date: 2017-10 Impact factor: 7.892
Authors: Cristina Sempio; Marilyn A Huestis; Susan K Mikulich-Gilbertson; Jost Klawitter; Uwe Christians; Thomas K Henthorn Journal: Br J Clin Pharmacol Date: 2020-01-20 Impact factor: 4.335
Authors: Anna Mazur; Cheryl F Lichti; Paul L Prather; Agnieszka K Zielinska; Stacie M Bratton; Anna Gallus-Zawada; Moshe Finel; Grover P Miller; Anna Radomińska-Pandya; Jeffery H Moran Journal: Drug Metab Dispos Date: 2009-04-01 Impact factor: 3.922
Authors: Cristina Sempio; Marilyn A Huestis; Susan K Mikulich-Gilbertson; Jost Klawitter; Uwe Christians; Thomas K Henthorn Journal: Br J Clin Pharmacol Date: 2020-01-20 Impact factor: 4.335
Authors: Cristina Sempio; L Cinnamon Bidwell; Kent Hutchison; Marilyn A Huestis; Jost Klawitter; Uwe Christians; Thomas K Henthorn Journal: Ther Drug Monit Date: 2021-08-01 Impact factor: 3.118